Last updated on August 2019

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive With or Without Mixed Features


Brief description of study

  1. To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features; 2) To evaluate the efficacy and safety of cariprazine at a target dose of 1.5 mg/d compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features who were initially stabilized on a target dose of 3.0 mg/d

Clinical Study Identifier: NCT03573297

Find a site near you

Start Over

Research Centers of America

Hollywood, FL United States
2.38miles
  Connect »

Sooner Clinical Research

Hallandale Beach, FL United States
9.55miles
  Connect »